Индийская Ameenji Rubber подписала стратегическое лицензионное соглашение с южнокорейским Macroad

Ameenji Rubber Limited (BSE Scrip Code: 544555) today announced the signing of a strategic Technology License Agreement with Macroad Co., Ltd., a specialized industrial player based in the Republic of Korea. The agreement secures the company advanced cross-border manufacturing capabilities as part of its ongoing product diversification strategy. Core Commercial Terms & Financial Outlay The technology transfer protocol establishes a clear financial and operational framework for the multi-year partnership: Exclusive Jurisdiction: Ameenji Rubber has been granted an absolute exclusive license to use, deploy, and leverage the incoming technology within the geographic boundaries of India. Operational Scope: The mandate covers the end-to-end industrial lifecycle-specifically the manufacturing, cross-channel marketing, and commercial sale of designated licensed products. Upfront Licensing Fee: The company will pay an initial technology license fee of USD 300,000 (approximately ₹2.5 crore), structured to be paid out in clear, milestone-linked operational phases. Royalty Structure: A running royalty pegged at 2.5% of the Net Sales Amount of the licensed products will be payable to the South Korean licensor, subject to definitive contract terms. Agreement Tenure: The contract specifies an initial duration of five years starting from the effective date, with built-in provisions for extension based on performance parameters. Strategic Alignment and Balance Sheet Impact The agreement is designed to enhance Ameenji's overall engineering base, allowing the domestic manufacturer to add sophisticated, high-performance polymer or rubber-integrated applications to its existing product portfolio. By onboarding an established international technical base, the company avoids prolonged internal research and development cycles, reducing the time-to-market for these new specialized products. Financially, the phased fee structure limits immediate cash flow strain on the company's balance sheet. Linking future payouts to a 2.5% net sales royalty keeps the ongoing cost of technology directly tied to the commercial success and revenue velocity achieved within the Indian market.